Phenylephrine Drugs Global Market Report 2025

The phenylephrine drugs market size has grown rapidly in recent years. It will grow from $25.44 billion in 2024 to $28.03 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. Key drivers of this historical growth include the increased incidence of cold and flu, a surge in allergic rhinitis cases, a rising preference for over-the-counter treatment options, the expanding trend of self-medication, and a higher volume of surgical interventions.

The phenylephrine drugs market size is expected to see strong growth in the next few years. It will grow to $40.83 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. Factors contributing to this future growth include greater healthcare spending in developing nations, expanded application in treating hypotension in critical care settings, a growing aging population, enhanced public awareness regarding nasal care, and wider adoption of combination therapy options. Prominent trends anticipated in the forecast period include innovations in nasal delivery technologies, enhancements in drug formulation stability, progress in nasal spray technologies, integration of drug-device combinations, and digital monitoring solutions for over-the-counter drug usage.

The rising incidence of respiratory diseases is expected to drive the growth of the phenylephrine drugs market in the coming years. Respiratory diseases refer to any conditions that affect the respiratory system, including the lungs and airways involved in breathing. A significant contributor to the increase in these diseases is air pollution, which damages lung tissue, impairs respiratory function, and triggers illnesses such as asthma. Phenylephrine drugs alleviate symptoms of respiratory diseases by acting as nasal decongestants. They constrict blood vessels in the nasal passages, which reduces swelling and enhances airflow, thereby relieving symptoms like nasal congestion, sinus pressure, and breathing difficulties associated with colds, allergies, and sinus infections. For example, in November 2023, the National Asthma Council, an Australia-based non-profit organization, reported that in 2022, Australia recorded 467 asthma-related deaths, including 299 females and 168 males, an increase from 355 deaths in 2021. Thus, the increasing incidence of respiratory diseases contributes significantly to the growth of the phenylephrine drugs market.

Major companies operating in the phenylephrine drugs market are focusing on innovative formulations, such as ready-to-use vials, to improve convenience, reduce preparation time, and enhance patient safety. Ready-to-use vials contain pre-mixed, pre-measured drug solutions that are immediately ready for administration, eliminating the need for further dilution or preparation. These vials help reduce dosing errors, speed up drug administration in emergency settings, and ensure consistent drug potency and sterility. For instance, in December 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company known for manufacturing generic injectable and oral formulations, launched its ready-to-use Phenylephrine HCl Injection, USP, in the U.S. under the brand name IMMPHENTIV. This product is available in 500 mcg/5 mL and 1,000 mcg/10 mL vials and is the first FDA-approved 1,000 mcg/10 mL formulation in the U.S. It is intended to raise blood pressure in adults experiencing clinically significant hypotension due to vasodilation during anesthesia, offering hospitals a standardized, pre-diluted option to reduce medication errors and support patient safety.

In June 2022, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, acquired generic injectable products from Eton Pharmaceuticals Inc. for an undisclosed sum. The acquisition was aimed at expanding and strengthening Dr. Reddy’s institutional business in the U.S. by adding affordable injectable medications with limited competition that address critical care needs. This move enhances patient access to essential products. Eton Pharmaceuticals Inc., a U.S.-based pharmaceutical company, specializes in the development and commercialization of phenylephrine-based medications.

Major players in the phenylephrine drugs market are Pfizer Inc., Procter And Gamble Co., Johnson And Johnson Consumer Inc, Bayer AG, GlaxoSmithKline PLC, Sandoz Group AG, Hikma Pharmaceuticals USA, Siegfried AG, Perrigo Company PLC, Amneal Pharmaceuticals LLC, Civica, Xellia Pharmaceuticals USA LLC, Camber Pharmaceuticals, Exela Pharma Sciences, Eton Pharmaceuticals, SOLA Pharmaceuticals, Fresenius Kabi USA, Somerset Therapeutics, Meitheal Pharmaceuticals, Novadoz Pharmaceuticals LLC.

North America was the largest region in the phenylephrine drugs market in 2024. The regions covered in phenylephrine drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the phenylephrine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Phenylephrine drugs are formulations that include phenylephrine, a synthetic sympathomimetic amine widely utilized as a decongestant, vasopressor, and mydriatic agent. It acts by stimulating alpha-1 adrenergic receptors, resulting in vasoconstriction (narrowing of blood vessels), which helps reduce nasal swelling, raise blood pressure, or dilate pupils, depending on how the drug is administered and its intended therapeutic purpose.

Phenylephrine drug products are primarily available in forms such as tablets, syrups, eye drops, and others. Tablets, being solid and portable dosage forms, offer accurate dosing and ease of consumption. They are commonly used to treat conditions like colds, nasal congestion, allergic reactions, eye disorders, and more. These medications can be taken orally or via parenteral routes and are distributed through a range of channels including hospital pharmacies, retail drugstores, and online platforms.

The phenylephrine drugs market research report is one of a series of new reports that provides phenylephrine drugs market statistics, including phenylephrine drugs industry global market size, regional shares, competitors with an phenylephrine drugs market share, detailed phenylephrine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the phenylephrine drugs industry. The phenylephrine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The phenylephrine drugs market consists of sales of oral decongestant tablets, sudafed PE, neo-synephrine, and phenylephrine HCl injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.